迪哲醫藥(688192.SH):DZD8586和DZD6008最新研究成果在2025年美國臨牀腫瘤學會年會上公佈
格隆匯5月23日丨迪哲醫藥(688192.SH)公佈,公司宣佈,其自主研發的兩款源頭創新藥物DZD8586和DZD6008將於2025年美國臨牀腫瘤學會(ASCO)年會上,分別報告在B細胞非霍奇金淋巴瘤(B-NHL)和非小細胞肺癌(NSCLC)領域的三項最新研究進展。這進一步彰顯了公司在血液腫瘤與肺癌領域全球差異化競爭的新優勢。其中,DZD8586治療慢性淋巴細胞白血病/小淋巴細胞淋巴瘤(CLL/SLL)的彙總分析結果將以口頭報告形式公佈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.